Please enable JS




1.Park JY et al. Neurotoxin impurities: A Review of threats to Efficacy. Plast Recontr Surg Glob Open. 2020;8(1):e2627

2.Kerscher M, et al. IncobotulinumtoxinA: A Highly Purified and Precisely Manufactured Botulinum Neurotoxin Type A. J Drugs Dermatol. 2019 Jan 1;18(1):52-57

3.XEOMIN® Approved Product Information. July 2014.

4.Prager W et al. Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study. Clin Interv Aging. 2013; 8: 449-456

5.Rappl T et al. Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clin Cosmet Investig Dermatol. 2013 Sep 24; 6:211-19.

6.Imhof M, Kühne U. A Phase III Study of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines. J Clin Aesthest Dermatol: 2011; 4(10):28-34

7.Frevert J & Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics. 2010; 4: 325-332



+852 2119 2250